Dupixent’s global net sales grew 38% in a single quarter. The stock is priced at a lower multiple than its own decade median. Those two facts sit in tension, and examining whether that tension is justified by the underlying fundamentals is what this analysis explores.
Regeneron spent most of the 2010s as a one-drug company, betting its future on Eylea, an injection that slows the kind of vision loss that strikes millions of older adults. That bet paid off spectacularly. Then came Dupixent, a treatment for inflammatory conditions from eczema to asthma, developed with Sanofi, and the company’s revenue more than doubled in four years. By the early 2020s, Regeneron was keeping roughly fifty cents of every revenue dollar as profit, a margin that almost no manufacturer of any kind achieves. The question today is whether a string of pipeline setbacks, a softening Eylea franchise, and a market that has already repriced the stock sharply upward over the past year have left the math and the mood in balance, or whether one of them is wrong.
The quick read
Regeneron’s filed numbers show a business generating nearly $1.3 billion in operating income in a single quarter, sitting on cash that exceeds its entire debt load by a factor of more than five, and keeping roughly 78 cents of every product-sales dollar after manufacturing costs. The stock trades at a price-to-earnings multiple that our data puts at the 65th percentile of its own decade range, meaning the market is paying a bit above its historical average but not at a premium that requires heroic assumptions. The open question is whether Dupixent can keep growing fast enough to offset a shrinking Eylea franchise and absorb the cost of a very large annual research budget, because if it cannot, the current multiple has less room than it looks.
What the filings actually show
The 10-Q filed July 30, 2026 for the quarter ended June 30 is the most recent filed period. Total revenue came in at $4.3 billion for the quarter, and operating income was $1.29 billion, meaning the company converted roughly thirty cents of every revenue dollar into operating profit after paying its scientists, its salespeople, and its factories. GAAP gross margin on product sales was 78%, which is what remains of each dollar of sales after the direct cost of making the drug. Think of it this way: a factory that sells a widget for $1.00 and spends $0.22 making it keeps $0.78 before any other bill arrives. Regeneron’s factories are that efficient.
The cash position is the other number worth holding. As of June 30, 2026, the company held cash and marketable securities that exceeded total debt by more than five times over. That balance sheet gives management unusual freedom to absorb a clinical failure without reaching for a lender.
The full-year picture from the 10-K for fiscal year 2025 shows revenue of $14.3 billion and a net margin of roughly 31%, approximately flat with the prior year. Growth has slowed from the pandemic-era peak: revenue fell sharply in 2022 when COVID antibody sales collapsed, recovered modestly through 2023 and 2024, and is now growing at a more measured pace. That deceleration is the context the current price has to justify.
The franchise pulling the cart
Dupixent is doing the heavy lifting. Global net sales reached $6.0 billion in Q2 2026, up 38% from the same quarter a year earlier. To put that in proportion: Dupixent alone in one quarter generated more revenue than many mid-sized pharmaceutical companies produce in a full year. The drug keeps earning new approvals, most recently for chronic spontaneous urticaria in young children in April 2026, and each new indication opens a new patient population without requiring a new molecule.
Eylea is the counterweight. The original formulation faces biosimilar competition, and the newer Eylea HD, approved in 2023 and granted extended dosing intervals through April 2026, has not fully replaced lost volume. U.S. net sales for the combined Eylea franchise fell meaningfully in early 2026 compared with the same period a year prior. Roche’s competing drug Vabysmo is taking share. The franchise that built Regeneron is contracting, and Dupixent is compensating, but the arithmetic only works as long as Dupixent’s growth rate stays well above Eylea’s decline rate.
The pipeline bet
Regeneron is spending roughly $6 billion on internal research and development in 2026, plus a substantial additional sum in U.S. capital expenditures on manufacturing and research infrastructure. Together, that is more than the company’s entire annual revenue just five years ago, directed at building the next generation of products. The pipeline produced a genuine win on August 19, 2026, when the FDA approved Pasatru for fibrodysplasia ossificans progressiva, a rare and devastating condition in which soft tissue gradually turns to bone. The patient population is small, so the commercial impact will be limited, but the approval demonstrates that the research engine is still producing.
The setbacks are equally real. In May 2026, a Phase 3 melanoma trial for fianlimab failed, and the stock dropped sharply in premarket trading on the news. In August 2026, a uveitis study was terminated after an unfavorable benefit-risk assessment. These are not unusual outcomes in drug development, where most programs fail, but they are a reminder that the research budget is a wager, not a guarantee. Cemdisiran monotherapy for myasthenia gravis is expected to launch in the U.S. in Q4 2026, and Phase 3 data for several other programs are anticipated in late 2026, so the next few months will test whether the pipeline can add a second growth engine alongside Dupixent.
Math versus mood
“The math” is what the filed fundamentals justify on their own terms. “The mood” is what the market is currently paying, which reflects expectations, sentiment, and the crowd’s collective guess about the future. The gap between them is where the interesting question lives.
Our data puts Regeneron’s current price-to-earnings multiple at 16.9 times, against a decade median of 15.9 times, at the 65th percentile of its own history. The price-to-sales ratio sits at a similar position relative to history. Stock analysis data through August 2026 shows a forward multiple that prices in meaningful earnings growth over the next year. BofA Securities, in a July 2026 note cited by MarketBeat, revised its valuation estimate upward and cited Dupixent, Eylea, and Libtayo as the primary drivers of its revised view, illustrating the bull case among sell-side analysts who follow the company. Citi, by contrast, revised its estimate downward to $700 and moved to a more cautious stance after the melanoma trial failure, illustrating the bear case among sell-side analysts who follow the company, a gap that illustrates how differently informed people read the same pipeline.
The math says: a business with 78% gross margins, more cash than debt, and a flagship drug growing at 38% annually is not obviously expensive at a below-median multiple. The mood says: the stock has already risen sharply over the past year, the multiple expansion that accompanied Dupixent’s early growth phase has already occurred, meaning further re-rating would require additional catalysts, and the next leg requires the pipeline to deliver. If cemdisiran launches cleanly in Q4 2026 and the obesity program advances, the forward multiple has room to compress further as earnings rise. If the pipeline disappoints again, the current price embeds assumptions that the filed numbers alone do not yet support.
That tension, between a balance sheet that looks conservative and a growth story that still depends on drugs not yet approved, is the central analytical question the filed numbers leave open.
Reading the numbers
- Q2 2026 revenue: $4.3 billion. What it is: total sales for the three months ended June 30, 2026, per the 10-Q filed July 30, 2026. What it means here: annualized, this pace would put full-year revenue well above the $14.3 billion recorded in FY2025, suggesting acceleration. Everyday version: a business that sold roughly $39 million of product every single day of the quarter.
- Gross margin: 78%. What it is: the share of each product-sales dollar left after the direct cost of manufacturing the drug. What it means here: Regeneron’s factories are among the most efficient in the industry, leaving a large cushion to fund research and still generate profit. Everyday version: a bakery that charges $10 for a loaf and spends $2.20 on flour, labor, and the oven keeps $7.80 before paying rent or the manager’s salary.
- Net cash position: $15.1 billion. What it is: cash and marketable securities minus total debt, as of June 30, 2026. What it means here: the company could pay off every dollar it owes and still have enough left over to buy a mid-sized pharmaceutical company outright. Everyday version: a household that owes $27,000 on a car loan but has $151,000 in the bank.
- P/E multiple: 16.9 times (65th percentile of own decade). What it is: the price tag per dollar of annual profit, a multiple being the ratio of stock price to earnings per share. What it means here: the market is paying slightly above its own historical average for this business, not a bargain but not a bubble. Everyday version: a rental property that historically sold for about 16 times annual rent is now listed at 17 times, a modest premium that requires the rent to keep growing to justify.
- Dupixent Q2 2026 global net sales: $6.0 billion, up 38% year-over-year. What it is: the revenue from Regeneron’s largest drug in a single quarter, per AlphaStreet’s Q2 2026 results summary. What it means here: one drug is growing fast enough to offset Eylea’s decline and still expand total company revenue. Everyday version: one product line growing so quickly that it adds the equivalent of a new mid-sized business to the portfolio every year.
For the standing yardsticks on Regeneron Pharmaceuticals: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Regeneron Pharmaceuticals.
Sources
- REGN 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- REGN 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- AlphaStreet: Regeneron Q2 2026 financial results
- BioPharma Dive: Pasatru FDA approval, August 2026
- Big Molecule Watch: Eylea HD extended dosing approval, April 2026
- Stock Analysis: REGN valuation statistics, August 2026
- MarketBeat: REGN analyst consensus, August 2026
- Investing.com: Regeneron Q2 2026 earnings call transcript
